Assessment of cost aspects of prevention of excessive thromboformation in patients with COVID-19 in Ukraine
DOI:
https://doi.org/10.24959/sphhcj.25./354Keywords:
Coronavirus disease (COVID-19); excessive thrombosis; preventive treatment; oral anticoagulants.Abstract
COVID-19 is a multisymptomatic infectious viral disease, one of the main complications of which is excessive blood clot formation, which can lead to myocardial infarction and stroke.
The aim of the study was to assess the cost aspects of market offers of medicines recommended for the prevention of excessive thrombosis in patients who have had COVID-19 and are prone to thrombosis.
Materials and methods. To conduct the study, data from the State Register of Medicines of Ukraine, Compendium, and the Register of Wholesale Prices for Medicines.
The data of the Protocol "Provision of medical care for the treatment of coronavirus disease (COVID-19)" has been systematized and summarized.
Additionally, international recommendations for providing care to patients with COVID-19 were studied through Embase Global Health, Medline, PubMed.
The following methods were used: systematic review, documentary, bibliographic, statistical, analytical, comparative, generalizing, informational.
Results. In Ukraine, the protocol "Providing medical care for the treatment of coronavirus disease (COVID-19)" is in effect, which recommends that after COVID-19, patients with a risk of excessive thromboembolism continue anticoagulant therapy with oral anticoagulants, which include direct thrombin inhibitors (Dabigatran) and direct factor Xa inhibitors (Rivaroxaban, Apixaban). As a result of the conducted studies, it was found that the cost of a 30-day course of preventive treatment for a patient is: apixaban 2.5 mg - 1398.00 UAH; pradakasa 300 mg - 1523.40 UAH; xarelto 15 mg/20 mg - 1871.94 UAH. The cost of pharmacotherapy with apixaban 2.5 mg is the lowest compared to xarelto by 1.3 times.
Conclusions. Prophylactic pharmacotherapy with oral anticoagulants for patients at risk of excessive thromboembolism after COVID-19 should lead to normalization of blood coagulation status and prevent thromboembolism
References
World Health Organization. Coronavirus disease (COVID-19). URL: https://www.who.int/ru/health-topics/coronavirus#tab=tab_1
National Heart, and Blood Institute. COVID-19 and blood. URL: https://www.nhlbi.nih.gov/covid/blood
State Register of Medicines of Ukraine. Information Fund. URL: http://www.drlz.com.ua/
Online Directory of Medicines Compendium URL: https://compendium.com.ua/uk/
Register of Wholesale and Retail Prices for Medicines as of October - November 2024. URL: https://moz.gov.ua/uk/reestr-optovo-vidpusknih-cin-na-likarski-zasobi
Internet - resource Tabletki.ua. URL: https://tabletki.ua/
Order of the Ministry of Health of Ukraine dated 02.04.2020 № 762 (as amended) “Protocol for providing medical care for the treatment of coronavirus disease (COVID-19)”. URL: https://www.dec.gov.ua/wp-content/uploads/2023/05/protokol-covid2023.pdf
Khanyukov O.O., Sapozhnychenko L.V., Kalashnikova O.S., Somilo O.V.
Okhotnik E.O. Risk factors and prevention of thrombosis in patients with COVID-19. Ukrainian Medical Journal. 2021. № 2 (142) DOI: 10.32471/umj.1680-3051.142.205394
Sanidas E., Grassos C., Papadopoulos D., Velliou M., Barbetseas J. Pulmonary Embolism Prophylaxis in Patients With COVID-19: An Emerging Issue. Heart Lung Circ. 2021. October; 30(10). R. 1435-1441. DOI: 10.1016/j.hlc.2021.04.018
Siegler J.E., Dasgupta S., Abdalkader M., Penckofer M., Yaghi S., Nguyen T. Cerebrovascular Disease in COVID-19. Viruses. 2023. July 21; 15(7). R. 1598. DOI: 10.3390/v15071598.
Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. № 395 (10223). P. 497–506. DOI: 10.1016/S0140-6736(20)30183-5
Zozulya I.S., Mardzvik V.M., Mardzvik M.V. Vascular neurological complications in patients with COVID-19. Ukrainian Medical Journal. 2021. № 2 (142) DOI:10.32471/umj.1680-3051.142.204731.
Dudchenko M.O., Zayets S.M., Prykhidko R.A. Current aspects of the development of coagulopathy in patients with COVID-19 infection: a review of the literature. Medical and environmental problems. 2021. № 5-6. P. 7-11. DOI: 10.31718/mep.2021.25.5-6.02
Atanu Chandra, Uddalak Chakraborty, Shrestha Ghosh, Sugata Dasgupta, Anticoagulation in COVID-19: current concepts and controversies, Postgraduate. Medical Journal. 2022. № 98. P. 395-402. DOI: 10.1136/postgradmedj-2021-139923
Law of Ukraine “On the State Budget of Ukraine for 2025”. URL: https://zakon.rada.gov.ua/laws/show/4059-20#Text
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
